The reversal of fortunes for Gilead Sciences' Trodelvy in an advanced form of breast cancer is complete, with an FDA approval unlocking what could be a sizeable new market for the TROP2-targeting ...

In March, Gilead Sciences reported positive results for its TROPiCS-02 study of Trodelvy, but the guarded tone of the announcement led to speculation that the data was not as strong as hoped.

Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term investors. See more on GILD stock here.

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...

Gilead Sciences, Inc. (Gilead) is providing supply of Trodelvy. In late May 2024, Debiopharm and MEDSIR announced a collaboration to evaluate the clinical combination of Debio 0123, an oral ...

IDEAYA is the study sponsor and Gilead will provide the supply of Trodelvy to Ideaya. IDE397 monotherapy or in combination with Trodelvy has not been approved by any regulatory agency and the ...

Entered into an additional clinical study collaboration and supply agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy, Gilead's Trop-2 directed ADC ...

Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

GILD has multiple ongoing studies looking to expand Trodelvy’s label further. However, Gilead’s efforts to expand Trodelvy’s label suffered a setback due to the failure of its late-stage ...

Trodelvy, meanwhile, remains the only approved ... oncology and inflammation will help to drive the next wave of growth for Gilead. We have no major loss of exclusivity until late 2033, and ...

Oppenheimer raised the firm’s price target on Gilead (GILD) to $132 from $115 and keeps an Outperform rating on the shares. The firm says that ...